Neuropathic Pain – Current Treatment – Current Treatment: Physician Insights – Neuropathic Pain (US)
The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. Despite the increasing availability of generic options across these drug classes, current analgesics fall short in providing adequate relief because of associated side effects, prolonged titration, inadequate dosing, poor compliance, and low treatment satisfaction. The successful launch of a novel analgesic for neuropathic pain will require a granular understanding of treatment patterns in key gateway indications (e.g., postherpetic neuralgia, painful diabetic neuropathy) for emerging neuropathic pain drugs.
QUESTIONS ANSWERED
- What percentage of neuropathic patients suffer from comorbidities (e.g., depression, insomnia, kidney disease)?
- How has neurologists’ and PCPs / GPs’ prescribing changed in the past year? What changes are they anticipating in the coming year?
- How do PCPs / GPs and neurologists differ in their prescribing practices?
- What nonpharmacological approaches are clinicians using instead of or in addition to prescription drug therapy for neuropathic pain?
- What are the most common reasons for discontinuation of mainstay drugs for neuropathic pain?
- What factors most influence treatment initiation for neuropathic pain?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 50 U.S. PCPs / GPs and 50 U.S. neurologists fielded in July 2024
Key companies: Pfizer, Scilex, Azurity Pharmaceuticals, Almatica, Grünenthal / Averitas Pharma, Janssen, Assertio Therapeutics, AstraZeneca
Key drugs: Gabapentin, pregabalin, Qutenza, ZTLido, Gralise, Horizant, amitriptyline, duloxetine, venlafaxine, milnacipran, topiramate, NSAIDs, opioids, tramadol, tapentadol
